Press Releases
November 18, 2020
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314
June 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
August 27, 2019
Pionyr Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
July 10, 2018
Pionyr Immunotherapeutics and ProBioGen Initiate a Second Immuno-Oncology Contract Development and Manufacturing Project
December 13, 2017
Pionyr Immunotherapeutics Completes $62 million Series B Financing to Advance Antibody-Based Therapeutics Targeting the Tumor Microenvironment
January 4, 2017
Pionyr Immunotherapeutics Closes Financing with Focus on Developing Antibody-based Immuno-oncology Therapeutics